Category: Healthcare and Medical News
Gb Sciences' innovative approach harnesses the power of plant-based treatments as simplified mixtures that target dangerous hyperinflammatory responses to viral infections.
Gb Sciences' anxiety formulations were previously identified using the company's AI-driven PhAROS™ platform, and they have now been evaluated using preclinical zebrafish models of stress at the National Research Council of Canada.
President and Chief Science Officer Dr. Andrea Small-Howard demonstrates the platform's utility for predicting novel plant-inspired drug candidates and describes its role in Gb Sciences' future successes
As mental health disorders increasingly impact global populations, Gb Sciences is developing psychotropic but non-psychedelic treatments for anxiety and depression that compete with the emerging billion-dollar psychedelic companies.
At the Annual Summit, Dr. Andrea Small-Howard is presenting a Keynote Address that includes data from case studies demonstrating the utility of Gb Sciences' proprietary PhAROS drug discovery platform.
On March 25, the University of Seville, Chaminade University, and Gb Sciences co-published the results from Gb Sciences-sponsored study in the International Journal of Pharmaceutics. Gb Sciences' proprietary, time-released, oral nanoparticle technology improved the efficacy of cannabis-based terpenes in modulating a known pain receptor in this study.
As published in the journal Food and Chemical Toxicology, the biopharmaceutical drug development firm's sponsored research used co-cultured human, primary immune cells as a model to evaluate the ability of selected Cannabis constituents to decrease inflammation.
Dr. Andrea Small-Howard discusses the company's novel process for developing disease-specific, cannabinoid-based therapeutics.
As published in Frontiers in Pharmacology, the biopharmaceutical drug development firm's sponsored research has identified and validated cannabinoid ratio-controlled, Minimum Essential Mixtures (MEM) for the treatment of Parkinson's disease symptoms
Biopharmaceutical research company pursues faster route for drug discovery using PhAROS™, Gb Sciences' AI-enabled drug discovery platform, and through efficiency in their drug development pipeline leveraging strong relationships